New oral care probiotic created by Ostia Sciences and Expert’Biome CDMO by Lallemand

In a recent press release, Lallemand announced that Ostia Sciences Inc. and Lallemand's Expert’Biome CDMO have created, a new oral care probiotic which is ready to begin clinical trials.¹

The strain in the new oral care probiotic is called Streptococcus salivarius (SALI-10). Ostia Sciences is looking to begin clinical trials regarding oral health applications. As mentioned in the press release,¹ pre-clinical findings found that “this strain produces a bacteriocin, named Salivaricin 10, the world’s first phosphorylated lantibiotic, which will be tested in clinical trials to evaluate its ability to maintain a healthy oral microbiome, in addition to other beneficial effects such as supporting a healthy immune response.”

Dr. Abdelahhad Barbour, CEO of Ostia Sciences, said,¹ “After securing full intellectual property (IP) rights, we are ready to advance our research and support the development of our SALI-10 probiotic, targeting oral and respiratory health.”

The partnership of Expert’Biome CDMO and Ostia Sciences involved lab-scale production which was used to find the bioprocess involved with balancing yield and viability. Additionally, the companies needed to scale up to 150 L where they were able to confirm scalability and robustness.¹ According to the press release¹, these findings were made at Lallemands’s French GMP pharma plant, where formulation trials were also performed.

“Leveraging our lab and plant capacity, along with our experienced team, we supported Ostia Sciences from end-to-end in developing their next-generation probiotics. We chose to formulate lozenges, a dosage form particularly suited for slow dissolution in the mouth, which is the site of action for SALI-10,” commented Laurie Rey, head of Expert’Biome CDMO by Lallemand.¹

Barbour further mentioned,¹ “Expert’Biome’s regulatory support team assisted in submitting our application to the National Regulatory Authority. It was reassuring to rely on experts with the necessary knowledge to navigate regulatory waters.”

The companies are planning on beginning clinical trials soon and anticipate preliminary results by the end of this year.¹ Following the trials, Ostia Sciences plans to market the new oral care probiotic in the start of 2026.

Reference

1. Ostia Sciences and Expert’biome CDMO by Lallemand celebrate a major milestone for producing a new oral care probiotic https://www.lallemand-health-solutions.com/en/news-trends/press-releases/ostia-sciences-and-expertbiome-cdmo-by-lallemand-celebrate-a-major-milestone-for-producing-a-new-oral-care-probiotic/ (accessed May 27, 2025).